Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to $48.8 million.

  • Usana Health Sciences' Cost of Revenue rose 2434.73% to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.0 million, marking a year-over-year increase of 1516.51%. This contributed to the annual value of $161.2 million for FY2024, which is 876.15% down from last year.
  • Latest data reveals that Usana Health Sciences reported Cost of Revenue of $48.8 million as of Q3 2025, which was up 2434.73% from $50.2 million recorded in Q2 2025.
  • Usana Health Sciences' Cost of Revenue's 5-year high stood at $67.8 million during Q1 2022, with a 5-year trough of $38.6 million in Q4 2024.
  • Moreover, its 5-year median value for Cost of Revenue was $48.5 million (2023), whereas its average is $48.2 million.
  • Per our database at Business Quant, Usana Health Sciences' Cost of Revenue surged by 2516.77% in 2021 and then plummeted by 3152.62% in 2022.
  • Over the past 5 years, Usana Health Sciences' Cost of Revenue (Quarter) stood at $50.7 million in 2021, then dropped by 8.45% to $46.4 million in 2022, then fell by 8.85% to $42.3 million in 2023, then fell by 8.9% to $38.6 million in 2024, then rose by 26.62% to $48.8 million in 2025.
  • Its Cost of Revenue was $48.8 million in Q3 2025, compared to $50.2 million in Q2 2025 and $52.4 million in Q1 2025.